ALNYLAM PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
May 11, 2020 at 04:50 pm EDT
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 11, 2020 (May 6, 2020 )
Alnylam Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware
001-36407
Sector Update: Health Care Stocks Flat to Higher Premarket Monday
Apr. 08
MT
Sector Update: Health Care
Apr. 08
MT
Alnylam Pharmaceuticals Says Phase 2 Trial for Zilebesiran Meets Primary Endpoint
Apr. 08
MT
ANALYST RECOMMENDATIONS : Chevron, Take-Two, Coinbase, Netflix, American Tower...
Apr. 08
Transcript : Alnylam Pharmaceuticals, Inc. - Special Call
Apr. 07
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
Apr. 07
CI
Transcript : Alnylam Pharmaceuticals, Inc. Presents at Canaccord Genuity ?Genetic Medicine for Generalists?, Mar-25-2024 01:00 PM
Mar. 25
Transcript : Alnylam Pharmaceuticals, Inc. Presents at Stifel Virtual 2024 CNS Day, Mar-20-2024 10:00 AM
Mar. 20
Transcript : Alnylam Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 10:15 AM
Mar. 12
Alnylam Pharmaceuticals Says Phase 2 Study of Hypertension Drug Zilebesiran Meets Primary Endpoint
Mar. 05
MT
Transcript : Alnylam Pharmaceuticals, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 09:10 AM
Mar. 05
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran Is Added to Standard of Care Antihypertensives
Mar. 05
CI
Alnylam Pharmaceuticals Insider Sold Shares Worth $4,540,071, According to a Recent SEC Filing
Mar. 01
MT
Alnylam Pharmaceuticals Insider Sold Shares Worth $455,357, According to a Recent SEC Filing
Feb. 29
MT
How long will this bullish phase last?
Feb. 26
ANALYST RECOMMENDATIONS : AbbVie, Doordash, Eli Lilly, Moderna, Hiscox...
Feb. 26
ANALYST RECOMMENDATIONS : Airbnb, Conagra Brands, Berkshire Hathaway, Meta Platforms, Unilever....
Feb. 21
North American Morning Briefing : Earnings Back in -2-
Feb. 20
DJ
Chardan Cuts Price Target on Alnylam Pharmaceuticals to $225 From $250, Expects Topline Results in Mid-2024, Maintains Buy Rating
Feb. 16
MT
Goldman Sachs Downgrades Alnylam Pharmaceuticals to Neutral From Buy, Cuts Price Target to $173 From $230
Feb. 16
MT
ANALYST RECOMMENDATIONS : Coinbase, Fortinet, Nike, Chipotle, Nvidia...
Feb. 16
Alnylam Pharmaceuticals' Shares Fall on Q4 Revenue Miss
Feb. 15
MT
Wolfe Research Initiates Coverage on Alnylam Pharmaceuticals With Peer Perform Rating
Feb. 15
MT
Sector Update: Health Care Stocks Edge Higher Premarket Thursday
Feb. 15
MT
Transcript : Alnylam Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 15, 2024
Feb. 15
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Companyâs lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.
More about the company
Last Close Price
143.8
USD
Average target price
220
USD
Spread / Average Target
+52.99%
Consensus
1st Jan change
Capi.
-24.87% 18.18B +4.09% 43.84B +47.24% 41.25B +9.45% 41.68B -10.92% 27.04B +9.32% 25.53B +29.70% 12.29B +1.28% 12.29B +7.78% 11.15B -17.68% 9.98B
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1